reports
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
- ING Helpdesk
Benelux Morning Notes
Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
UCB Presents supportive three-year Bimzelx data in HS at EHSF
UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...
- Guy Sips
- Jacob Mekhael
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
UCB Model update ahead of FY25 results
Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
UCB Kygevvi receives positive CHMP opinion in ultra-rare disease TK2d
Friday during trading hours, UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of pediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. Following the positive CHMP opinion...
Participation notifications by UBS Group AG
Participation notifications by UBS Group AG Press release Regulated information Brussels, January 29, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), UBS Group AG recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total 21 January 2026 0.00% 0.00% 0.00% 23 ...
Notifications de participation par UBS Group AG
Notifications de participation par UBS Group AG Communiqué de presse Information réglementéeBruxelles, le 29 janvier 2026 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), UBS Group AG a envoyé récemment à Solvay les notifications de transparence suivante indiquant avoir franchi le seuil de 3%. Voici un résumé des notifications: Date de dépassement de seuil Droits de vote Instruments financiers équivalents Total 21 janvier 2026 0,00% 0,00% 0,00% 23 janvie...
Participatiemeldingen van UBS Group AG
Participatiemeldingen van UBS Group AG Persbericht Gereglementeerde informatie Brussel, 29 januari 2026 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft UBS Group AG onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de bewegingen: Datum waarop de drempel werd overschreden Stemrechten Aan stemrechten gelijkgestelde financiële instrumenten Totaal 21 januari 2026 0,00% 0...
Participation notifications by Citigroup Inc.
Participation notifications by Citigroup Inc. Press release Regulated information Brussels, January 28, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total January 19, 2026 0.56% 2.51 3.06% ...
Notifications de participation par Citigroup Inc.
Notifications de participation par Citigroup Inc. Communiqué de presse Information réglementée Bruxelles, le 28 janvier 2026 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), Citigroup Inc. a envoyé récemment à Solvay les notifications de transparence suivantes indiquant avoir franchi le seuil de 3%. Voici un résumé des notifications: Date de dépassement de seuil Droits de vote Instruments financiers équivalents Total 19 janvier 2026 0,56% 2,51 3,06% 22 ja...
Participatiemeldingen van Citigroup Inc.
Participatiemeldingen van Citigroup Inc. Persbericht Gereglementeerde informatie Brussel, 28 januari 2026 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft Citigroup Inc. onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de bewegingen: Datum waarop de drempel werd overschredenStemrechtenAan stemrechten gelijkgestelde financiële instrumentenTotaal19 januari 20260,56%2,513,06%22...
- ING Helpdesk
Benelux Morning Notes
Ahold Delhaize: Conditional approval for the acquisition of Delfood / Bekaert: Acquires Bridgestone's €80m tyre cord business in China and Thailand / KPN: In-line Q4, 2026 guidance, cash returns / NSI: Results in line, further vacancy weighing on 2026 and cautious tone on new developments / UCB: Cimzia included in Medicare's price negotiations for 2028
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Hoste
Solvay Taking a more cautious stance, lowering target price
Increased pressure in the soda ash market prompts us to take a more conservative approach with regards to contract terms for the coming years, resulting in a reduction of our group EBITDA forecasts for 2026-2028 by between 6-11%. The dividend policy of a stable to increasing dividend from a € 2.43 base looks increasingly generous as servicing the dividend representing the vast majority of current FCF generation, limiting the group's ability to pursue other growth initiatives. Despite the attract...
- Stijn Demeester
Solvay/Attractive yield, limited near-term catalysts/HOLD (previously ...
We trim our target price for Solvay to €26 per share (from €30) on the back of lower estimates and downgrade our recommendation from Buy to HOLD. Solvay trades at an attractive dividend yield but otherwise offers too few near-term share price catalysts given ongoing headwinds in some of its core segments.
Solvay SA: 1 director
A director at Solvay SA bought 1,000 shares at 24.900EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- David Vagman
- CFA
- Maxime Stranart
UCB/Bimzelx continues its exceptional launch/BUY
We reiterate our BUY rating and raise our target price from €257 to €310. UCB finished the year strongly, after upgrading its guidance for a second time in FY25. This upgraded guidance was mainly driven by an exceptional performance for Bimzelx, the group's key growth engine and which continues to surprise to the upside. This gives us comfort into our peak sales of €8.5bn for Bimzelx by 2032F, especially as the performance of Bimzelx in Hidradenitis Suppurativa remains strong. Alongside Bimzelx,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.